Newsroom | 5368 results

PORTO, Portugal--(BUSINESS WIRE)--To mark World Parkinson’s Day, Bial today launches “Dialogues with Parkinson’s”....

CHICAGO--(BUSINESS WIRE)--Emalex Biosciences received a patent covering an orally disintegrating tablet (ODT) formulation of ecopipam, an investigational D1 antagonist...

GUILFORD, Conn.--(BUSINESS WIRE)--Next-gen Swoop system and latest Optive AI software receive CE & UKCA marks, bringing Hyperfine’s most advanced portable MRI tech to European markets....

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research study led by Dr. David Beers and Dr. Stanley Appel at the Houston Methodist Neurological Institute. The study included the longitudinal measurement of well-characterized serum biomarkers of lipid peroxidation (4-hydroxy-2-nonenal [4-HNE]), systemic inflammation (lipopolys...

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events: 25th Annual Needham Virtual Healthcare Conference Fireside Chat Date and Time: Thursday, April 16, 2026 at 3:00 PM EDT Webcast...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today the closing of a definitive agreement to acquire the U.S. sales and distribution rights for a portfolio of seven branded products from Assertio Holdings, Inc. (Nasdaq: ASRT). The acquisition expands Cosette’s branded portfolio and adds the U.S. rights to SYMPAZAN®, a growing, patent-protected asset, further advancing Cosette’s disciplined growth strategy. SY...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 69,140 shares of the Company’s common stock to four new employees (the “Inducement Grants”) on April 6, 2026 (the “Grant Date”). The Inducem...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference...

SAN FRANCISCO--(BUSINESS WIRE)--Today, Rune Labs announced the launch of a personalized AI companion to provide always-on support for people with Parkinson’s disease. Powered by Anthropic's Claude and built on Rune Labs' proprietary longitudinal dataset, comprising millions of hours of wearable data and FDA-cleared symptom algorithms, StrivePD Guardian continuously analyzes patients' real-time data to deliver timely, context-aware guidance on symptoms, medications, daily experiences, and care g...

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that Kevin Finney, President and Chief Executive Officer, and Will Stratton, Chief Business Officer, will participate in the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026. Mr. Finney and Mr. Stratton will present on Wednesday, April 15, 2026, at 11:00 a.m. ET and parti...